KCNAB3

Summary

KCNAB3 (potassium voltage-gated channel subfamily A regulatory beta subunit 3, HGNC:6230) is a protein-coding gene on chromosome 17p13.1, encoding Voltage-gated potassium channel subunit beta-3 (O43448). Regulatory subunit of the voltage-gated potassium (Kv) channels composed of pore-forming and potassium-conducting alpha subunits and of regulatory beta subunit.

This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. The encoded protein is one of the beta subunits, which are auxiliary proteins associating with functional Kv-alpha subunits. The encoded protein forms a heterodimer with the potassium voltage-gated channel, shaker-related subfamily, member 5 gene product and regulates the activity of the alpha subunit.

Source: NCBI Gene 9196 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 77 total
• MANE Select transcript: NM_004732

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6230
Approved symbol	KCNAB3
Name	potassium voltage-gated channel subfamily A regulatory beta subunit 3
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	AKR6A9, KCNA3B
Ensembl gene	ENSG00000170049
Ensembl biotype	protein_coding
OMIM	604111
Entrez	9196

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000303790, ENST00000570587, ENST00000570852, ENST00000572275, ENST00000574006, ENST00000576981, ENST00000910604, ENST00000910605, ENST00000939113, ENST00000954807

RefSeq mRNA: 1 — MANE Select: NM_004732 NM_004732

CCDS: CCDS11124

Canonical transcript exons

ENST00000303790 — 14 exons

Exon	Start	End
ENSE00001144991	7925097	7925183
ENSE00001300284	7921859	7923179
ENSE00001326879	7929194	7929856
ENSE00003461556	7927344	7927423
ENSE00003487641	7927783	7927826
ENSE00003508312	7924415	7924500
ENSE00003520196	7924145	7924265
ENSE00003599307	7923456	7923544
ENSE00003623376	7925931	7925975
ENSE00003624606	7927657	7927694
ENSE00003643707	7923711	7923831
ENSE00003648219	7925683	7925726
ENSE00003679671	7923968	7924062
ENSE00003689309	7926059	7926103

Expression profiles

Bgee: expression breadth ubiquitous, 166 present calls, max score 96.53.

FANTOM5 (CAGE): breadth broad, TPM avg 2.7819 / max 163.1432, expressed in 542 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164333	2.7819	542

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	96.53	gold quality
cerebellar hemisphere	UBERON:0002245	96.05	gold quality
cerebellar cortex	UBERON:0002129	95.81	gold quality
cerebellum	UBERON:0002037	92.70	gold quality
body of uterus	UBERON:0009853	89.84	gold quality
ventricular zone	UBERON:0003053	88.69	gold quality
right frontal lobe	UBERON:0002810	87.96	gold quality
ganglionic eminence	UBERON:0004023	87.38	gold quality
anterior cingulate cortex	UBERON:0009835	84.52	gold quality
cingulate cortex	UBERON:0003027	84.47	gold quality
left uterine tube	UBERON:0001303	82.74	gold quality
cortical plate	UBERON:0005343	82.27	gold quality
granulocyte	CL:0000094	81.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	81.13	gold quality
prefrontal cortex	UBERON:0000451	79.68	gold quality
metanephros cortex	UBERON:0010533	79.58	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	79.46	gold quality
neocortex	UBERON:0001950	79.08	gold quality
sural nerve	UBERON:0015488	78.51	gold quality
frontal cortex	UBERON:0001870	77.92	gold quality
stromal cell of endometrium	CL:0002255	77.71	gold quality
adenohypophysis	UBERON:0002196	77.18	gold quality
smooth muscle tissue	UBERON:0001135	77.10	gold quality
peripheral nervous system	UBERON:0000010	76.66	gold quality
tibial nerve	UBERON:0001323	76.66	gold quality
pituitary gland	UBERON:0000007	76.47	gold quality
amygdala	UBERON:0001876	76.01	gold quality
right ovary	UBERON:0002118	75.76	gold quality
cerebral cortex	UBERON:0000956	75.26	gold quality
right lobe of thyroid gland	UBERON:0001119	75.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.61

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

60 targeting KCNAB3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-567	99.63	68.57	1219
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-578	99.46	68.36	1787
HSA-MIR-889-5P	99.41	68.75	1025
HSA-MIR-135A-5P	99.36	71.85	1601
HSA-MIR-135B-5P	99.36	71.63	1613
HSA-MIR-4786-3P	99.36	68.35	1390
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-1206	99.30	69.32	1016
HSA-MIR-1264	99.25	66.81	1317
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-376A-3P	99.06	69.17	1128
HSA-MIR-376B-3P	99.06	69.17	1128
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-7851-3P	98.72	64.88	980

Literature-anchored findings (GeneRIF, showing 1)

• H258R mutation in KCNAB3 gene in a family with genetic epilepsy and febrile seizures plus. (PMID:32990398)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	KCNAB3	ENSDARG00000074320
mus_musculus	Kcnab3	ENSMUSG00000018470
rattus_norvegicus	Kcnab3	ENSRNOG00000008480
caenorhabditis_elegans		WBGENE00009980
caenorhabditis_elegans		WBGENE00009981
caenorhabditis_elegans		WBGENE00012722
caenorhabditis_elegans		WBGENE00012723
caenorhabditis_elegans		WBGENE00015307

Paralogs (16): AKR7A2 (ENSG00000053371), KCNAB2 (ENSG00000069424), AKR1B1 (ENSG00000085662), AKR1A1 (ENSG00000117448), AKR1D1 (ENSG00000122787), AKR1C2 (ENSG00000151632), AKR7A3 (ENSG00000162482), AKR1E2 (ENSG00000165568), KCNAB1 (ENSG00000169282), AKR1C1 (ENSG00000187134), AKR1C3 (ENSG00000196139), AKR1B10 (ENSG00000198074), AKR1C4 (ENSG00000198610), AKR7L (ENSG00000211454), AKR1B15 (ENSG00000227471), AKR1C8 (ENSG00000264006)

Protein

Protein identifiers

Voltage-gated potassium channel subunit beta-3 — O43448 (reviewed: O43448)

Alternative names: K(+) channel subunit beta-3, Kv-beta-3

All UniProt accessions (3): O43448, I3L0P1, I3L4I8

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory subunit of the voltage-gated potassium (Kv) channels composed of pore-forming and potassium-conducting alpha subunits and of regulatory beta subunit. The beta-3/KCNAB3 subunit may mediate closure of potassium channels. Increases inactivation of Kv1.5/KCNA5 alpha subunit-containing channels. May display nicotinamide adenine dinucleotide phosphate (NADPH)-dependent aldoketoreductase activity. The binding of oxidized and reduced NADP(H) cofactors may be required for the regulation of potassium channel activity.

Subunit / interactions. Forms heteromultimeric complex with alpha subunits. Interacts with KCNA5 and KCNB2.

Subcellular location. Cytoplasm.

Tissue specificity. Brain specific. Most prominent expression in cerebellum. Weaker signals detected in cortex, occipital lobe, frontal lobe and temporal lobe. Not detected in spinal cord, heart, lung, liver, kidney, pancreas, placenta and skeletal muscle.

Similarity. Belongs to the shaker potassium channel beta subunit family.

RefSeq proteins (1): NP_004723* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005399	K_chnl_volt-dep_bsu_KCNAB-rel	Family
IPR005402	K_chnl_volt-dep_bsu_KCNAB3	Family
IPR005983	K_chnl_volt-dep_bsu_KCNAB	Family
IPR023210	NADP_OxRdtase_dom	Domain
IPR036812	NAD(P)_OxRdtase_dom_sf	Homologous_superfamily

Pfam: PF00248

UniProt features (29 total): binding site 19, sequence conflict 5, compositionally biased region 2, chain 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43448-F1	85.55	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 131 (proton donor/acceptor)

Ligand- & substrate-binding residues (19): 229; 230; 255; 284; 286; 287; 288; 289; 295; 305; 364; 366 …

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1296072	Voltage gated Potassium channels
R-HSA-112316	Neuronal System
R-HSA-1296071	Potassium Channels

MSigDB gene sets: 97 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS, STAEGE_EWING_FAMILY_TUMOR, RORA1_01, REACTOME_POTASSIUM_CHANNELS, AAGCCAT_MIR135A_MIR135B, GOBP_MONOATOMIC_CATION_TRANSPORT, DOUGLAS_BMI1_TARGETS_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS, EGR1_01, GOBP_REGULATION_OF_TRANSPORT, GOBP_REGULATION_OF_MONOATOMIC_ION_TRANSPORT, AP2_Q6_01, GOBP_TRANSMEMBRANE_TRANSPORT, GOBP_REGULATION_OF_POTASSIUM_ION_TRANSPORT

GO Biological Process (5): potassium ion transport (GO:0006813), regulation of potassium ion transmembrane transport (GO:1901379), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), potassium ion transmembrane transport (GO:0071805)

GO Molecular Function (5): voltage-gated potassium channel activity (GO:0005249), potassium channel regulator activity (GO:0015459), oxidoreductase activity (GO:0016491), transmembrane transporter binding (GO:0044325), protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), plasma membrane (GO:0005886), voltage-gated potassium channel complex (GO:0008076), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Potassium Channels	1
Neuronal System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
potassium channel activity	2
cellular anatomical structure	2
metal ion transport	1
regulation of potassium ion transport	1
potassium ion transmembrane transport	1
regulation of monoatomic cation transmembrane transport	1
transport	1
monoatomic ion transport	1
transmembrane transport	1
potassium ion transport	1
monoatomic cation transmembrane transport	1
voltage-gated monoatomic cation channel activity	1
ion channel regulator activity	1
catalytic activity	1
protein binding	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
potassium channel complex	1
plasma membrane protein complex	1
transmembrane transporter complex	1

Protein interactions and networks

STRING

1731 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KCNAB3	KCNA4	P22459	897
KCNAB3	KCNA5	P22460	836
KCNAB3	KCNB2	Q92953	791
KCNAB3	PANX1	Q96RD7	739
KCNAB3	KCNA1	Q09470	728
KCNAB3	KCNA2	P16389	711
KCNAB3	KCNV1	Q6PIU1	611
KCNAB3	KCNH3	Q9ULD8	591
KCNAB3	KCNK6	Q9Y257	536
KCNAB3	KCNC1	P48547	507
KCNAB3	KCNG1	Q9UIX4	507
KCNAB3	KCNK13	Q9HB14	506
KCNAB3	CACNB1	Q02641	485
KCNAB3	KCNF1	Q9H3M0	478
KCNAB3	AKR1D1	P51857	476

IntAct

12 interactions, top by confidence:

A	B	Type	Score
MAPK8	WDR62	psi-mi:“MI:0914”(association)	0.730
KCNAB3	GMDS	psi-mi:“MI:0915”(physical association)	0.560
KCNAB3	PLEKHF2	psi-mi:“MI:0915”(physical association)	0.560
KCNAB3	KCNAB2	psi-mi:“MI:0914”(association)	0.500
KCNAB3	KCNAB2	psi-mi:“MI:0915”(physical association)	0.500
MAPK8	WDR62	psi-mi:“MI:0914”(association)	0.350
KCNAB3	DHPS	psi-mi:“MI:0914”(association)	0.350
KCNAB3	GMDS	psi-mi:“MI:0915”(physical association)	0.000
KCNAB3	PLEKHF2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): KCNAB3 (Affinity Capture-MS), KCNAB2 (Affinity Capture-MS), HDAC6 (Affinity Capture-MS), DHPS (Affinity Capture-MS), MAD1L1 (Affinity Capture-MS), KCNAB2 (Affinity Capture-MS), KCNAB3 (Affinity Capture-MS), HDAC6 (Affinity Capture-MS), MAD1L1 (Affinity Capture-MS), DHPS (Affinity Capture-MS), KCNAB3 (Affinity Capture-MS), KCNAB3 (Two-hybrid), PLEKHF2 (Two-hybrid), KCNAB2 (Affinity Capture-MS), KCNAB3 (Affinity Capture-MS)

ESM2 similar proteins: A4K436, A6NMX2, F1QWK4, O43272, O43448, O54783, O95154, O97583, P17516, P28492, P38918, P52849, P52850, P70694, P97382, Q0VGM9, Q13011, Q148G5, Q1JQD7, Q1XAA8, Q3KRC5, Q3ZKN0, Q571F8, Q5E9M9, Q5I0K3, Q5R7C9, Q5RE34, Q5RFG0, Q5RJZ1, Q5RKZ7, Q63494, Q64323, Q6H1L8, Q6PCB7, Q6W8P9, Q8CG45, Q8CG76, Q8IXI1, Q8N0X4, Q8NHP1

Diamond homologs: A0A0U5GHU6, B9WYE6, C7ZBE5, C8VQ93, E9FCP6, G2TRN6, M2YMU7, O05408, O43448, O59826, P40690, P43547, P54569, P63143, P63144, P77256, P77735, Q01333, Q01752, Q02895, Q13303, Q14722, Q28528, Q3L181, Q4PJK1, Q75ZG2, Q75ZG3, Q9P7U2, Q9PTM4, Q9PWR1, Q9XT31, A2XRZ0, B8ASB2, C6TBN2, F4HPY8, M2YJQ2, O22707, O23016, O43488, O95154

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	67
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2305 predictions. Top by Δscore:

Variant	Effect	Δscore
17:7923552:C:CT	acceptor_gain	1.0000
17:7923553:A:T	acceptor_gain	1.0000
17:7923827:TAGCC:T	acceptor_gain	1.0000
17:7923828:AGCC:A	acceptor_gain	1.0000
17:7923829:GCC:G	acceptor_gain	1.0000
17:7923830:CC:C	acceptor_gain	1.0000
17:7923830:CCC:C	acceptor_gain	1.0000
17:7923831:CC:C	acceptor_gain	1.0000
17:7923831:CCTGG:C	acceptor_loss	1.0000
17:7923832:C:CC	acceptor_gain	1.0000
17:7923832:C:T	acceptor_gain	1.0000
17:7923833:T:G	acceptor_loss	1.0000
17:7923840:C:CT	acceptor_gain	1.0000
17:7923840:C:T	acceptor_gain	1.0000
17:7923841:A:T	acceptor_gain	1.0000
17:7924144:CCAAT:C	donor_gain	1.0000
17:7924148:T:C	donor_gain	1.0000
17:7925095:AC:A	donor_gain	1.0000
17:7925096:CC:C	donor_gain	1.0000
17:7925099:T:A	donor_gain	1.0000
17:7925929:A:AC	donor_gain	1.0000
17:7925929:ACTGT:A	donor_gain	1.0000
17:7925930:C:CC	donor_gain	1.0000
17:7925930:CTGT:C	donor_gain	1.0000
17:7925930:CTGTC:C	donor_gain	1.0000
17:7927322:G:C	donor_gain	1.0000
17:7927342:A:AC	donor_gain	1.0000
17:7927342:ACTTT:A	donor_gain	1.0000
17:7927343:C:CC	donor_gain	1.0000
17:7927343:CTTTC:C	donor_gain	1.0000

AlphaMissense

2584 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:7924450:A:G	W226R	0.989
17:7924450:A:T	W226R	0.989
17:7925696:C:A	K175N	0.988
17:7925696:C:G	K175N	0.988
17:7927398:G:T	A117D	0.988
17:7924447:C:A	G227W	0.986
17:7925702:G:C	S173R	0.986
17:7925702:G:T	S173R	0.986
17:7925704:T:G	S173R	0.986
17:7923719:A:G	L347P	0.983
17:7924249:G:T	A243D	0.983
17:7923544:G:T	A350E	0.982
17:7926063:A:G	W149R	0.982
17:7926063:A:T	W149R	0.982
17:7927377:A:G	L124P	0.982
17:7924435:A:G	W231R	0.981
17:7924435:A:T	W231R	0.981
17:7925159:A:G	L188P	0.980
17:7924489:C:G	A213P	0.979
17:7927374:A:G	F125S	0.979
17:7926086:C:T	G141E	0.977
17:7925141:T:A	D194V	0.976
17:7925698:T:C	K175E	0.976
17:7926086:C:A	G141V	0.976
17:7924491:C:G	R212P	0.975
17:7925135:A:T	V196D	0.975
17:7925162:C:G	R187P	0.974
17:7927797:G:A	S91F	0.974
17:7924446:C:T	G227E	0.973
17:7926077:A:G	L144P	0.973

dbSNP variants (sampled 300 via entrez): RS1000043109 (17:7926325 G>A), RS1000263522 (17:7926401 G>A), RS1001142904 (17:7930848 A>T), RS1001270703 (17:7924968 A>C,G), RS1001324997 (17:7929256 T>G), RS1001342729 (17:7925247 A>G), RS1001691331 (17:7922987 G>A,C,T), RS1002148154 (17:7928000 A>G), RS1002550957 (17:7929527 C>T), RS1002717824 (17:7921660 T>C), RS1002822579 (17:7930937 T>C), RS1003103856 (17:7924609 T>A,C), RS1003146868 (17:7928298 TC>T), RS1003437872 (17:7929299 C>A,G,T), RS1003589009 (17:7928566 C>G,T)

Disease associations

OMIM: gene MIM:604111 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST006190_14	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	7.000000e-18
GCST006190_56	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	2.000000e-21
GCST006192_58	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	2.000000e-12
GCST006192_85	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	3.000000e-07
GCST006193_47	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	4.000000e-18
GCST006193_85	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	1.000000e-20
GCST006195_36	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	4.000000e-07
GCST006195_77	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	2.000000e-12
GCST010002_119	Refractive error	3.000000e-22

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006335	systolic blood pressure

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation	2
aristolochic acid I	increases expression	1
bisphenol A	decreases expression	1
kojic acid	decreases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
Sunitinib	decreases expression	1
Arbutin	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	increases expression	1
Okadaic Acid	increases expression	1
Acrylamide	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_YA60	IDG-HEK293T-KCNAB3-V5-OE	Transformed cell line	Female

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice